This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-4298 injection in patients with malignant solid tumors.
Subjects must voluntarily agree to participate in the trial and sign a written informed consent form.
ECOG performance score of 0-1.
Life expectancy ≥ 3 months.
Have at least one measurable tumor lesion per RECIST v1.1.
Subjects with active central nervous system metastases or meningeal metastases.
Suffering from other malignant tumors within five years before the first use of the drug.
History of serious cardiovascular and cerebrovascular diseases.
Clinically significant bleeding symptoms occurred within 3 months before the first dose of study drug.
Single group
SHR-4298 Injection
DrugSHR-4298 injection.
Incidence and severity of adverse events (AEs).
Incidence and severity of serious adverse events (SAEs).
Maximum Tolerated Dose (MTD).
Maximum Applicable Dose (MAD).
Overall response rate (ORR).
Duration of response (DoR).
Disease control rate (DCR).
Progression-free survival (PFS).
Click on the lead sponsor to view all of their trials.
